Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 10,000
- Avg volume
- 31,304
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company w...
Show more
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 713 335 5697
- Website
- https://propcitweb.ddns.net:83
- Address
- 9432 Katy Freeway, Houston, United States
Latest news
No headlines yet.
